The optimism for SLGT2 inhibitor treatment generally must remain cautious for FSGS treatment given currently available evidence, though disease heterogeneity of FSGS raises the possibility that some patients may benefit from SGLT2 inhibition. Here, SLC5A2 is linked to focal segmental glomerulosclerosis.